OBJECTIVE: Castration-resistant prostate cancer (CRPC), which occurs in 10-20% of patients with prostate cancer (PC), has had a historically poor prognosis. However, there are a number of emerging treatment options. The aim of this study was to describe the real-world treatment patterns of CRPC in Japan.
Introduction
The specific objectives are as follows:
• To identify the current treatment patterns for mCRPC
• To identify the current treatment patterns for pain among patients with mCRPC and symptomatic skeletal events (SSEs)
• To quantify the healthcare resource use burden of SSEs
Objectives
• Data from a total of 445 patients were collected. Patients were an average of 73.6 years old (SD=8. 3) , had been diagnosed with prostate cancer for 5.1 years (SD=6.2), and had been castration resistant for 2.3 years (SD=2.0). At diagnosis, 89.2% had ECOG 0-1, and 77.3% had a Gleason Score of 8-10. Furthermore, patients had an average of 7.9 (SD=12.4) bone metastasis sites, with 35% of these patients having other, non-visceral sites of metastasis (see Table 1 ).
Results
• The results show that current treatments for mCRPC in Japan still rely widely on the use of ADT as 1 st line therapy. However, with the advent of new options in recent years, an increasing shift to these new treatments is apparent.
• The use of novel anti-hormone therapies for mCRPC are well accepted in clinical practice in Japan, becoming more common than chemotherapy in later lines. The shift to using new therapies over ADT and chemotherapy in later lines shows that physicians are increasingly open to utilizing alternative effective treatments for their patients.
• The increasing use of bone management therapies (bisphosphonates, denosumab) as well as pain management therapies (NSAIDs and opioids) from the 1 st to 4 th lines also reflect the increasing need for SSE management, placing emphasis on symptom management by physicians for better clinical outcomes and improving the QOL of patients.
• The results also showed that patients with an SSE, compared with those without an SSE, consumed more medical resources, both on an in-patient and out-patient basis.
• This study reinforces the ongoing clinical challenges in the treatment of patients with mCRPC, particularly for those with SSEs and the need for early intervention with effective treatment for prevention of SSEs.
Conclusions
• Not all patient charts had complete data and, therefore, there were omissions in disease characteristics, treatments, and healthcare resource use among other variables.
-This could have influenced treatment pattern results (e.g., first-line treatments may have been different for those with versus without complete data).
-This may have also led to an underestimation of the number of patients with an SSE; indeed, the overall number of patients with SSE was low, limiting our statistical power when comparing the treatment patterns and outcomes of this group with patients without SSEs.
• Study physicians were all members of an Internet panel and therefore there may be differences in those who participated relative to the general population with respect to treatment practices and patient types they treat. 
Limitations
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Results
Study design
• A retrospective chart review study was conducted. Data were collected between December 2014 and February 2015 from urologists (N=176) in Japan who were recruited from two online physician panels.
-These panels, which include approximately 75% of the total physician population and over half of the urologists in Japan, consist of physicians who agree to participate in periodic survey research.
• Urologists who met eligibility criteria (e.g. spend at least 50% of their time in direct patient care, with at least 5 mCRPC patients under their care in the past month) and provided informed consent proceeded to an online data collection form.
• Physicians were asked to identify up to 3 patients who most recently visited their office and met eligibility criteria. The inclusion criteria were confirmed diagnosis of CRPC based on Japanese guidelines on Prostate Cancer [9] , metastatic with >=2 bone metastases and no visceral metastases, and had been diagnosed with PC for at least one year. Patients who were part of an investigational program with interventions outside of routine clinical practice were excluded.
Measures
• Patient demographics and disease history -Patients were described with respect to clinical and demographic factors including age, time since diagnosis, stage at diagnosis, metastases status, Gleason Score, and Eastern Cooperative Oncology Group (ECOG) performance status.
• Symptomatic skeletal events (SSEs) -The presence of an SSE was defined as the use of external beam radiotherapy (EBRT) to relieve skeletal symptoms, symptomatic pathological bone fractures (vertebral or non-vertebral), occurrence of spinal cord compression or a tumor related orthopedic surgical intervention.
• Treatment patterns and healthcare resource use -The information on medication use was collected via electronic survey from participating physicians to evaluate treatment patterns. Specific medications used for each patient, including most recent medication, second-most recent medication, and third-most recent medication were reported.
-Physicians also reported the healthcare resource use (i.e., the number of office visits and hospitalizations) for each patient, which was annualized.
Statistical analysis
• Treatment pattern variables were reported descriptively using frequencies and percentages for categorical variables and means and standard deviations for continuous variables.
• Differences between the use of treatments between patients with and without an SSE were compared using chi-square tests.
• Differences in annualized healthcare resource use between patients with and without an SSE (at any point in their last three treatment lines) were compared using a generalized linear mixed model (with patient nested within physician to account for non-independence of observation), controlling for variables which differed between these patient groups. Adjusted means were reported.
Methods Table 1. Demographics and disease history of patients with mCRPC (N=445)
• When physicians were asked about the treatment options they would use for their patients with mCRPC (without referring to patient charts), androgen deprivation therapy (ADT) (23.1%) and docetaxel (18.3%) were the most thought of to use in 1 st line, but enzalutamide (21.8%) and abiraterone were the most thought of to use (21.0%) in 2 nd line. Physicians thought of using docetaxel the most in the 3 rd and 4 th line (see Table 2 ).
*Based on N=444 due to missing data, **Based on N=91 due to missing data, ***Based on N=442 due to missing data
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• However, when actual treatment patterns were checked based on patient charts, it showed that ADT was the most commonly used CRPC treatment for patients in the 1 st (43.6%) to 4 th line (40.7%). This reflects the wide use of ADT in Japan that is acknowledged even in NCCN Guidelines [8] . Novel anti-hormones enzalutamide and abiraterone were not widely used in the 1 st Line, but showed more acceptance in later lines, reflecting their recent availability (used among 14.5% and 8.7%, respectively, of patients in 1 st line and 40.7% and 20.3%, respectively, in 4 th line). Cabazitaxel, a new chemotherapy, also showed increasing uptake from the 1 st to 4 th Line, though at a lower degree than the novel anti-hormones, possibly due to indication limitations. Docetaxel was seen to have lower use compared to the new medications beginning in the 2 nd to the 4 th line (see Table 3 ).
• An increasing use of bisphosphonates and denosumab could also be seen from 1 st to 4 th line, possibly reflecting management of symptomatic skeletal-events (SSEs) in patients with bone metastasis.
• NSAIDs and opioids were used frequently for pain management, showing increasing use from the 1 st Line to the 4th Line treatment, possibly reflecting advancing disease-related pain due to bone metastasis.
• Our data revealed that SSEs were uncommon, with only 3.2% , 3.4%, and 2.1% of patients experiencing an event during their current, most recent, and second-most recent regimen, respectively. This might be due to a certain degree of selection bias from the responding physicians in choosing patient charts, but may also reflect real-world evidence that SSEs are uncommon in Japan. Currently, no published data are available to show the prevalence of SSEs in CRPC in Japan.
• From our data, significant differences were seen between patients with SSEs and those without SSEs, in terms of management. The presence of SSEs was associated with an increased use of opioid analgesics and NSAIDs. Similarly, significant differences were seen for such as bisphosphonates. Furthermore, the use of palliative regimens such as strontium-89 and EBRT were also significantly different between the two sets of patients (all p<.05; see Table 4 ).
• Patients who experienced an SSE at any point (N=24) reported significantly more annualized post-SSE physician visits (Adjusted means=23.5 vs. 12.1) and general ward hospitalizations (Adjusted means=2.2 vs. 0.7) than those without an SSE (N=421; all p<.05) (see Figure 1) . Table 3 . Treatments used by line for patients with mCRPC (N=445)
Only patients with known first-line (N=401), second-line (N=281), third-line (N=148), and fourth-line (N=59) treatments were included. ADT = androgen deprivation therapy; NSAIDs = non-steroidal anti-inflammatory drugs; CAB = combined androgen blockade; EBRT = external beam radiotherapy Note: Individual N's may not add up to total N due to elimination of low frequency items (<2) ADT = androgen deprivation therapy; NSAIDs = non-steroidal anti-inflammatory drugs; CAB = combined androgen blockade; EBRT = external beam radiotherapy *p<.05 between SSE and no SSE groups within each treatment line Figure 1 . Adjusted mean differences in annualized healthcare resource utilization between those with (N=24) and without an SSE (N=421).
Generalized linear mixed models were conducted (with patient nested within physician) specifying a negative binomial distribution and a log link function.
All models controlled for patient age, referral status, Gleason score at diagnosis, ECOG score at diagnosis, years being castrate resistant, other non-bone sites of metastases, years the treating physician has been in practice, region of treating physician, overall patient load of the treating physician in the past 3 months, the PC Stage IV M1 patient load in the past 3 months, and the mCRPC with 2+ bone (and no visceral) metastases patient load of the treating physician in the past 3 months.
